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Currently chemotherapy and radiotherapy are the most popular methods for cancer 
treatments after surgery, but lack of specificity and are thus toxic to the healthy human cells. 
Studies have shown that targeted therapies have been linked to activation of apoptosis signal 
pathways (cascade of caspases) in cancer cells including intrinsic and extrinsic pathways.  One 
of the major pathways leading to caspase activation involves the release of cytochrome-c from 
mitochondria. However, in some tumor cells this pathway is inactivated due to the mutation of 
mitochondria membrane stabilizing proteins (e.g. Bcl-2, Bcl-xL). Therefore, the overall objective 
of this proposal was to understand the mechanism and the kinetic of cytochrome-c release from 
the mitochondria, so novel and improved molecular target therapies can be developed against 
cancers. For this purpose, we have successfully constructed a cytochrome C-GFP reporter cell 
line using human lung cancer cells. The result from western blot confirmed the presence of the 
intact cytochrome C-GFP fusion protein in the reporter cell line. We investigated the release 
kinetics of cytochrome C-GFP in response to three different apoptosis-inducing reagents; 
TRAIL, Staurosporine, and Tarceva. The result from this study illustrated that the dynamic 
release of cytochrome C-GFP is dependent on the cell types and doses. We have also developed a 
system to investigate the anti-cancer drugs response in a sequence of time interval, Microfluidic 
Duration Device.  The microfluidic duration device with the reporter cell line can be further used 
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Cancer is one of the principal causes of death in the adult population. Currently, non-
invasive treatment for cancer is chemotherapy. In the last three decades, survival of cancer has 
been significantly improved by chemotherapy. However the success of cancer chemotherapy is 
still severely limited by the lack of selectivity of anti-cancer drugs to malignant cells leading to 
dose-limiting toxicity and the resistance of cancer cells to the conventional anti-cancer drugs. 
Therefore, with better understanding of molecular signaling pathway that linked to activation the 
apoptosis in cancer cell line, we can develop a novel target therapy that show more efficiency, 
good tolerability and less resistance profiles. By developing a reporter cell lines using human 
cancer cells, we can the study of anti-cancer drug mechanisms systematically in cell death 
pathways. It may facilitate the development of molecular target therapy for cancer. 
 
1.1 Apoptosis  
Apoptosis, or programmed cell death (PCD), is involved in numerous cell processes 
including   cell development, elimination of damaged cells and maintenance of cell homeostasis. 
During apoptosis, various biochemical events occur inside the cell, which lead to morphological 
changes such as loss of cell membrane attachment, cell shrinkage, nuclear fragmentation, 
chromatin condensation, and chromosomal DNA fragmentation [1]. These events are carried out 
by intracellular protease enzymes called caspases that destroy a large set of cellular proteins 
important for cell viability. Two well known pathways that activate the caspase cascade are: a. 





1.1.1 Extrinsic Pathway 
The extrinsic pathway triggers apoptosis independently of p53gene, in response to pro-
apoptotic ligands (e.g. tumor necrosis factor (TNF)-related apoptosis-inducing ligand or Apo2 
ligand as illustrated in Figure 1) [2,3]. These ligands activate specific pro-apoptotic receptors, 
known as death receptors (DR4 and DR5). The activation of death receptors (DR4 and DR5) 
then leads to the recruitment of the adaptor Fas associated death domain (FADD). FADD then 
activates procaspases 8 and 10 which in turn form the death-inducing signaling complex (DISC).  
As a result, self-cleavage of procaspase-8 results in the activation caspase-8 [4, 5 ]. Caspase-8 
then cleaves procaspase-3 and -7 into caspase-3 and -7, which in turn trigger apoptosis. In a 
situation where there are insufficient quantities of caspase-8, -3, and -7, for the induction of 
apoptosis, the intrinsic pathway (see below) is activated through cleavage of BH3.  Interactive 
domain death agonist (BID) leads to the formation of truncated BID (tBID) by casapse-8, which 


















Figure 1. The extrinsic apoptotic pathway; Solid lines in the Figure correspond to the protein that is acting 
upon another molecule and dashed lines represent a cleavage event that is changing inactive form of protein 
to active form[9] 
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1.1.2 Intrinsic pathway 
The intrinsic pathway is dependent of p53 gene that is known as tumor-suppressor gene. 
DNA damage and other types of severe cell stresses trigger the p53 genes, as illustrated in Figure 
2 [6, 9]. In this pathway, mitochondria play an important role in the regulation of cell death and 
cell survival: mitochondrial function is regulated by the BCL-family, which in turn regulates the 
release of protein from the space between the mitochondrial inner and outer membrane. Once the 
proteins are released in the cytosol it activates caspase proteases which lead to cell death [7].  
The BCL-family is divided in two subgroups, pro-death (proapoptotic) members and anti-death 
(anti-apoptotic) members [10, 11, 12] Bak and Bax are prodeath members that have been 
categorized as the last gateway of cytochrome c release, and their homooligomerization on the 
mitochondrial membrane is essential for release [8]. The anti-death members of Bcl-2 family 
such as, Bcl-XL and McL-1 prevent mitochondrial protein release by interacting with and 
inhibiting both Bak/Bax and BH3-only proteins [8, 13].  
Upon a stimulus, the proapoptotic protein such as Bax undergoes conformational changes 
to form oligomers and translocates itself to mitochondria. Translocation of Bax to mitochondria 
leads to the release of cytochrome c [14, 15]. Once cytochrome c is released it interacts with the 
C-terminal WD40 repeats of Apaf-1 and is induced into a huge complex, known as an 
apoptosome. The formation of apopotosome leads to activation of the initiator caspase-9 [11, 
16]. Upon the activation of caspase-9 initiates the executioner caspases including caspase-3,-6, 
and -7, and consequently leading to cell apoptosis. On the other hand, the anti-apoptotic 
members of the BCL2 family, e.g. BCL2, BCLXL, and MCL1, regulate the mitochondria-
initiated caspase activation pathway by preventing the release of cytochrome c in the presence of 
apoptotic stimuli [17]. Deregulation in apoptosis signaling pathways may cause diseases, such as 
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cancers, immune diseases, and neurodegenerative disorders. In the last four decades, over 2 





















Figure 2. The intrinsic apoptotic pathway; Solid lines in the Figure correspond to the proteins that are acting 
upon another molecule and dashed lines represent a cleavage event that is changing inactive form of protein 




 In general, there is a cell cycle regulation of cell production in order to keep the number 
of any particular cell type constant. However when there is deregulation in the cell cycle it gives 
rise to clones of cells that develop into a tumor. Tumor is divided into two categories, cancerous 
(malignant) or noncancerous (benign). A malignant tumor penetrates the surround normal tissues 
and also tends to metastasize to invade distant organs. According to the American Cancer Society 
in 2012, the estimated amount of death due to cancer is 577,190 up by 14% from 2009 [18]. 
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1.2.1 General cancer treatment 
Current methods to treat cancer include conventional therapy such as chemotherapy, 
radiotherapy, vaccine, gene therapy and immunotherapy. Surgery is the original and still remains 
as the major therapeutic measure for tumors at earlier stages. One of the main disadvantages of 
surgical treatment is that not all the tumor is removed through this process, not to mention the 
added general risks that go along with surgery (such as  that of death in the removal of brain 
tumor). Radiotherapy involves using high energy radiation to locally eradicate cancerous cells 
while sparing normal ones. It is mainly used, in combination with surgery and/or chemotherapy, 
for non-metastatic or recurrent cancer treatment [19]. It is often used prior to surgery to reduce 
the size of a tumor, or after surgery to destroy any remaining cancer cells, and to relieve 
symptoms. However, the lack of specificity renders the procedure potentially toxic, as evidenced 
by it demonstrating the most discernible side effect due to its indifferent targeting of both 
cancerous and noncancerous cells.   
 
1.2.2 Target Therapy 
A new approach is to develop molecular target drugs to cure cancer. The main goal of 
targeted cancer therapies is to eliminate malignant cells without causing harm to the normal 
healthy cells. Many of these therapies focus on proteins that are involved in cell signaling 
pathways, which form a complex communication system that governs basic cellular functions 
and activities, such as cell division, cell movement, cellular response to specific external stimuli, 
and even cell death. By blocking the signals that tell cancer cells to grow and divide 
uncontrollably, targeted cancer therapies can help stop cancer progression and may induce 
cancer cell death through an apoptotic process [3]. Other targeted therapies can cause cancer cell 
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death directly, by specifically inducing apoptosis, or indirectly, by stimulating the immune 
 system to recognize and destroy cancer cells and/or by delivering toxic substances to them. 
Studies have shown that targeted therapies have been linked to the activation of apoptosis signal 
transduction pathways in cancer cells, including the aforementioned extrinsic and intrinsic 
pathways [20].  
1.3 Current obstacles/limitation of apoptosis detection in anti-cancer drug screening  
The process of drug discovery and delivery is limited by a number of challenges. One of 
the main challenges is the analysis of drug in cellular environment in a more accurate and rapid 
manner. Current conventional techniques for delivering time varying stimuli are not compatible. 
It requires carefully timed pipetting and multiple rinse steps to completely remove stimuli in 
mid-experiment. Perfusion culture systems have been used to overcome many of these obstacles 
by replenishing culture medium continuously; however most continuous-flow chambers 
accommodate only one experimental condition at a time, and as a result, they also limit 
throughput [21]. This need leads to the development of microfluidic devices. The microfluidic 
devices have been used for pre-clinical and clinical studies. They are very useful tools for target 
selection which can help in the manufacturing of new therapeutic product. These devices can 
address the inherent complexity of cellular systems with massive experimental parallelization 
and 4D (multiparameter outputs plus time) analysis and sorting of single cells [22]. One main 
advantage of utilizing this technology is that it requires low number of cell numbers, smaller 
reagent volumes. These devices are in microscale (µm) units that provide fast mass transfer 
kinetics, shorter reaction time and the possibility of parallel operation that provides the unique 
ability to monitor single-cell signaling dynamics [22, 23]. 
 
6 
In the microscale environment fluids exhibit unique characteristics dominated by laminar 
flow, diffusion, fluidic resistance, surface area to volume ratio, and surface tension. The flow 
behavior is usually characterized by Reynolds number, given by the equation: 
   
= ܍܀  ૄ/۲܃۴ 
 
(where F is the density, U is the average velocity of the flow, D is the equivalent hydraulic 
diameter of the microchannel, and µ is the fluid viscosity) [22,  23]. For most of the microfluidic 
system, the Reynolds number is limited to <100. The fluid flow under this condition is laminar 
with no inertia and allows the solute transport dominated by local diffusion [24]. These 
properties greatly enable accurate delivery of drugs, both spatially and temporally, and can help 
to study the cellular responses, static or kinetic, to novel targeted anticancer agents and 
pharmacological compounds. Increasing number of reports provide innovative solutions that 
reach beyond simple proof-of-principle studies to applications of microfluidics in drug discovery 
and clinical diagnostics [22]. 
 
1.4 Microfluidic Duration Device 
  In the present study, we are using the “Microfluidic Duration Device” system to study the 
dynamic release of cytochrome c in human lung cancer cell line under the stimulation of 
anticancer agents.  The idea of the device originally stems from the “Microfluidic flow-encoded 
switching device” network system described in [21]. The purpose of this device is to control the 
inlet flow ratio in time. The state of the network can be controlled dynamically, and cells 
throughout the network can be exposed to different stimulus regimens [21, 22]. As a result it will 
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provide a dynamic profile of cellular response to a stimulus (e.g., an anticancer drug). To 
demonstrate this approach, we will used our constructed PC-9 with cytochrome C-GFP cell line 
in the microfluidic duration device and stimulate with TRAIL to monitor the dynamic release of 
cytochrome C in real-time image by controlling the duration of drug delivery. For the future 
purposes, we can use this device with multiple drugs in a time interval-sequence that would help 
derive the optimal time window within which there is a synergistic drug response. For instance, 
these results can further improve target therapy in cancer treatment by suggesting different 
designs or implementations of the drugs within pharmaceutical devices that allow them to be 






























2. Objective of this study 
The main goal of cancer target therapy is to kill tumor cells without causing harm to 
normal cells.  Target therapy is mainly focus on proteins that are involved in cell signaling 
pathways, which form a complex communication system that governs basic cellular functions 
and activities. Studies have shown that intrinsic pathway is one of the major pathways that 
involve caspase activation. Importantly, caspase activation is triggered by the release of a pro-
apoptotic protein known as cytochrome c. However, the mechanism and kinetics of cytochrome-
c release under multiple stimuli is still questionable in different mammalian cancer cell line. The 
first aim of this project was to develop a human lung cancer reporter cell line, which contains 
cytochrome c-GFP fusion protein and monitor the real time response of anti-cancer drug. For this 
purpose, stable transfected human lung cancer cell line was constructed via the electroporation 
method. To study the apoptotic response of different drugs, the following apoptosis-inducing 
agents were investigated: TRAIL (TNF- Related Apoptosis Inducing Ligand), Staurosporine, 
Tarceva. According to the hypothesis, TRAIL and staurosporine should have different releasing 
time of cytochrome c as prior studies have shown that TRAIL induces apoptosis via extrinsic 
pathway while staurosporine induces apoptosis by release of cytochrome c via intrinsic pathway. 
TRAIL and staurosporine can be used as controls to study the natural product (Actein) to 
investigate if this natural product has a potential to induce apoptosis in human lung cancer cell, 
and if it does then what signaling pathway it triggers for apoptosis. We compared the releasing 
time of cytochrome c after induction of TRAIL, Staurosporine and Tarceva.  The second aim of 
this project was to combine the reporter cell line with “Microfluidic Duration Device” to study 




3. Materials and Methods  
 
3.1 Cytochrome-c GFP plasmid amplification and DNA Isolation 
DH5-α  bacterial  strain  was  transformed  with  the  pCytochrome C-GFP as shown in 
figure 3,  requested  from Douglas R.  Green Lab, which contained cytochrome C gene in-
frame fused with green fluorescent protein (GFP) gene [25]. Bacterial colonies containing the 
plasmid were separately amplified in 500 ml Lysogeny broth (LB medium) for 24 hours.  
After the amplification, DNA isolation was performed using the QIAGEN plasmid Maxi 
















3.2 Construction of reporter human lung cancer cell line 
 Cell culture: Human lung cancer cells (PC-9) were culture in RPMI 1640 ( ATCC, 
Manasssas, VA) media supplemented with 10% heat inactivated  fetal  bovine  serum (FBS, 
Atlanta Biologicals)  and  1%  penicillin (100 U/ml), streptomycin (100 mg/ml) (P/S; Gibco, 
Invitrogen)  at  37oC in  a  5%  CO2 in T75 flask.  
Stable Transfection: For the construction of stable reporter cell line containing cytochrome C-












Figure 3: Mouse cytochrome-c gene was ligated 
into pEGFP-N1 vector at Xhol and BamHI sites 
and GFP is on the c-terminal. 
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and centrifuged to obtain the cell concentration of 12 x106 cell/ml. The cell suspension of 5x106 
cell/ml was added to 0.4cm cuvette with 50µg of pCytochrome C-GFP in total 500µL volume.  
BioRad electroporator machine was used for electroporation with an electric impulse which was 
set for a 960µF capacitance and a 250V (voltage). After the impulse, the cells were immediately 
transferred into the 10 cm2 with 9ml of RPMI media. After 24 hours, the cells were fed with 
fresh RPMI growth medium. The expressions of fusion protein gene were analyzed through 
fluorescence microscopy after 48 hours at the wavelength of the excitation maximum 488 nm; 
emission maximum 507 nm. For the generation of stable cell lines, transfected PC-9 cells were 
selected in the presence of 650µg/ml Genet ic in (G418) for 2 weeks, and clones expressing 
mitochondrial cytochrome c-GFP were enriched.  
FACS sorting: After the two weeks allowed for stable tranfection, cloning rings were used to 
selected clones that expressed GFP signals. Those clones were sorted by fluorescence activated 
cell sorter machine (FACS) at MSKCC FACS facility.  The FACS machine was set up using 
non-transfected PC-9 cells (as negative control cells) and stable transfected cells expressing 
GFP signals. Based on the fluorescent threshold value, the cells expressing high GFP signals 
were sorted. The sorted cells were cultured in a T25 flask with RPMI 1640 medium.  
 
3.3 Characterization of the reporter cell line 
To confirm whether the fluorescent tag GFP is still fused with cytochrome-c gene, 
western blot analysis was performed. For cell lysis, a confluent T25 flask of stable transfected 
cells were trypsinized and washed three times using 1X Phosphate buffer saline (PBS).  Then 
cell pellet was gently resuspended in 1X extraction buffer [protease inhibitor; 0.1 mM PMSF, 1 
µg/ml leupeptin, 1 µg/ml aprotinin, 1µg/ml pepstatin], incubated in ice for 30 min and every 
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10 minutes cells were vortex. The cell extracts were separated from the cell debris by 
centrifugation at 16,000 g for 15 minutes at 40C. The protein content of the supernatant was 
determined by the Bradford assay and samples were stored at -80oC until use.   
For analysis, 40 µg of cell proteins were mixed with loading buffer, the mixture was 
boiled for 5 min and subjected to 15% SDS- PAGE gel at 150 V for 1h. The gel was 
electroblotted to an Immun-Blot PDVF ( Polyvinylidene diflouride ) membrane at 30 V for 16 h. 
Membranes were blocked for 1 h with 3% nonfat milk in TBS-T at room temperature and then 
incubated with an anticytochrome C (1:1000) and anti-EGFP (1:1000). The membrane were 
rinsed three time with 1X TBS-T buffer and incubated with horseradish-peroxidase-conjugated 
goat anti-mouse polyclonal antibody (1:5000) for 1h. After the secondary antibody incubation, 
the membranes were rinsed with 1X TBS-T buffer and bound antibodies were detected by using 
TMB solution, prepared according to the manufacture’s instruction (10 ml was added to each 
membrane for 15 min until the bands showed up.) 
 
3.4 Co-localization by Confocal Microscopy 
The reporter cell line gene expression was confirmed by co-expression of cytochrome c-
GFP with mitochondria using 2 m M Mitotracker Red CMXRos (Molecular Probes, Invitrogen). 
One day before the experiment, the reporter cells were seeded in 2 well chambers at the 
concentration of 23x104cell/ml and incubated at 370C. At the day of the experiment, one well of 
2-well chamber stained with 2mM of Mitotracker Red CMXRos (Molecular Probes, 
Invitrogen). After 15 minutes of incubation, cells were washed with 1XPBS and 500 µl of 
Serum Free Medium was added to each well. Confocal images of green cyctochrome-c GFP 
were collected using 488nm excitation light from an argon laser. Images of red MitoTrackerRed 
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CMXRos fluorescence were collected using a 568-nm excitation light from argon laser. Images 
were taken in z-stack for 3-D imaging analysis of the cells. A 3-D construction was done in 
LEICA software.  Co-localization analysis was done using Image J software.   
On the same day, another set of samples were prepared, cell culture procedure was 
followed as above. Prior to addition of Mitotracker Red CMRos, TRAIL at 100ng/ml was added 
to the 2 well chambers and incubated for 2 hours. After incubation, cells were washed twice 
with 1XPBS and then 2mM Mitotracker Red CMRos. For confocal imaging, the same 
procedure was followed as above.  
3.5 Monitoring the release of Cytochrome c after stimulation of anti-cancer drugs 
Stable transfected PC-9 cells expressing the cytochrome-c- GFP protein were seeded into 
a 12 well plate at the concentration of 0.5 x106 cell/ml per well. After 24 hours of incubation, the 
cell culture medium was changed into Serum free Medium (SFM) and cells were incubated in 
SFM for 2 hours. After 2 hours of incubation, different apoptosis inducing agents were added to 
the reporter cell line; 100ng/ml TRAIL was added to first three wells, 400ng/ml TRAIL was 
added to other three wells, 1mM Staurosporine at the other three wells. Time lapsed images 
were taken using Carl Zeiss microscope at 20X objective for 12 hours at 30 minute intervals.  
Similarly, another set of experiment was performed, where reporter cell were seeded into 
a 12 well plate at the same concentration of 0.5 x106 cell/ml per well. After 24 hours of 
incubation, cell culture medium was changed into SFM. After 2 hours of cell incubation at SFM, 
400ng/ml TRAIL was added to first three wells, 200nM Tarceva was added to the next three 
wells and nodrugs (control) on the three other wells. As mentioned above, time lapse images 
were recorded at 20X, for duration of 12 hours at 30 minute intervals. 
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3.6 Image Analysis 
For image analysis, Image-Pro software was used. All the fluorescence images were 
converted to grayscale. To avoid white noise, despeckle filter was selected with following 
settings: 7x7 despeckle and a sensitivity of 3. For background correction, three areas lacking in 
cells from the image were selected, and the mean value of these regions used as a background 
reference. This mean was subtracted from the despeckled image.  this, areas of interest (AOIs) 
were chosen by selecting a circle around the cells and recording the mean and standard deviation 
value for each AOI. For analysis, AOIs were randomly selected with three replicates per 
condition.  
To measure the duration/timing of cytochrome C-GFP release Image Pro software was 
used. The standard deviations of the average brightness of all the pixels in the image of user-
selected individual cells were measured. The standard deviation was higher when cytochrome C-
GFP was punctuated inside the mitochondria and low at diffusive.  The total average fluorescent 
intensity in single cells stayed the same as the cytochrome C-GFP was being released from 
mitochondria. We normalized standard deviation, where standard derivation is divide by its 
average (CV=STD/Mean). The sudden drop in normalized standard deviation (or Coefficient of 
Variance) corresponds to the timing of cytochrome-c GFP release in the cells as indicated in the 
quantitative analysis of time-lapse images. 
 
3.7 Fabrication of Microfluidic Duration Device 
 The conceptual drawing of Microfluidic Duration Device came from King, R.K and 
Sihong Wang [21]. Briefly, electronic drawings were made in AUTOCAD software. The 
dimensions of the device are: diameter of the experimental channels is 400µm, two inlet 
14 
diameters are 600 µm, and channel height is 100 µm. Manufacturing of the device was done by 
the general, standard protocol of PDMS. Briefly, the PDMS elastomer devices were molded from 
the masters using two-part Sylgard silicon elastomer (a mixture of 1:10 silicon elastomer and 
curing agent degassed and poured against the silicon master). Once cured, each PDMS device 
was punched with inlet/outlet holes, treated with oxygen plasma membrane , bonded to the glass 
slide by putting both treated surfaces in contact to each other immediately.  
3.8 Statistcal Analysis: 
Analysis of Variance (ANOVA) was performed within nodrug (Control) to determine if there is 
significant different in coefficient of variance at different time point (p<0.05). For all three 
treated group with drugs we performed two-tailed paired t-test with confidence interval of 95% 
to determine if there is any significant different in the distribution of GFP expression over 



























4.1 Cytochrome c-GFP reporter cell line 
In this study, we used the electroporation 
for the stable transfection of PC-9 cells (human 
lung cancer cells) with cytochrome C-GFP 
fusion protein gene. Transfected PC-9 cells 
with cytochrome C-GFP fusion protein 
expression were compared to transfected PC-9 cells with GFP expression using pd4EGFP 
(control vector). Figure 4A shows that the GFP expression in cytochrome C-GFP PC-9 cells is 
punctuated, but smooth in PC-9 cells transfected with the control plasmid (Figure 4B).  
FACS analysis performed before sorting allows the selection of the enclosed region, P4, 
as the cell population that contained high GFP signal as shown in Figure 5A. The cell population 
expressing GFP signal was 14%, and 74% of that population was not expressing GFP signal. 
14% of the cells with GFP expression were sorted, culture-expanded and frozen down. Figures 
5B, 5C depict the total population of PC-9 and PC-9 with cytochrome C-GFP after sorting. 
Figure 5D shows the fluorescence intensity of GFP signal within these two populations. The blue 
line histogram in Figure 5D represents the non-transfected PC-9 (as negative control) and the red 
line histogram represents the transfected PC-9 with cytochrome C-GFP. The statistical analysis 
illustrated that 85% if cytochrome C-GFP cells had GFP expression in R1 region while only 7% 






Figure 4: (A) PC-9 cells transfected with cytochrome c 
gene in-frame fused with green fluorescent protein 
(GFP) gene. (B) PC-9 cells transfected with pdEGFP 
plasmid (control) and images were taken with a 20X 















































Figure 5: (A) FACS analysis of PC-9 with cytochrome-c GFP before sorting, 14% of 
the cell population had the recombinant cytochrome –c GFP, (B)  Cell population of 
PC-9 cells after sorting, (C) Cell population with  GFP expression after sorting, (D) 
Histogram fluorescence intensity of two population. The R1 region showed that 85% in 








4.2 Confirmation of localization of cytochrome c-GFP within mitochondria  
Mitotracker red color fluorescent dye was used to confirm the punctuation of GFP within 
mitochondria. Using a confocal microscope operated under the two-channel measurement mode, 
channel 1 for Alex 488 and channel 2 for DsRed, series of images in z-direction were obtained at 
40X objective (Figure 6A, 6B). Figure 6A and 6B are from the middle layer of z-direction series 
of images, and the punctuation of GFP inside the mitochondria was clearly shown in Figure 6A. 
The location of mitochondria was observed using DsRed filter at 568nm excitation (Figure 6B). 
The overlay image demonstrated the co-localization of GFP signal inside the mitochondria 
(Figure 6C).   Quantitative co-localization analysis of overlay images was determined by 
Pearson's correlation coefficient using Image J software.  Pearson’s correlation coefficient of 
overlay image was Rp= 0.772, representing a clear correlation between the two colors; therefore, 
as the intensity value increases in channel 1(ch1), the value of intensity increases in channel 2 
(ch2).  From the series of images in z-direction overlay a 3-D animation image of cells with 










4.3 Confirmation of cytochrome C-GFP fusion protein expression  
A comparison of cytochrome C-GFP and cytochrome-c was obtained by western blotting. The 
result from membranes with anti-cytochrome C-GFP antibody showed two prominent bands, one 
between 89KDa & 36KDa and other below 18 KDa (Figure 7A). The band above 36 KDa 
corresponds to the cytochrome C-GFP molecular weight (at approximately 39 KDa) and the one  
Figure 6: Colocalization of cytochrome C-GFP 
with mitochondria. All the images were taken 
in 40X oil objective under confocal 
microscope. (A) Cytochrome C-GFP punctuate 
inside the mitochondria, (B) Cells were stained 
with Mitoctracker for mitochondria, (C) 
Overlay image of cytochrome  C-GFP with 
mitotracker (D) Quantitative analysis of 
colocalization image, where Rp=0.772, (E) 3-D 















below 18KDa band corresponds to endogenous cytochrome C, (which is approximately 12 KDa), 
as shown in Figure 7A. The anti-cytochrome C-GFP antibody recognizes these two bands 
because the cytochrome C- GFP reporter cell line contains both the endogenous cytochrome C as 
well as the cytochrome C-GFP fusion protein. A band at 39 KDa also illustrates that cytochrome 
C is still fused with GFP protein. Similarly, the membrane exposed to anti-EGFP antibody also 
shows a prominent band at around 39KDa confirming that GFP protein is still fused with 
cytochrome C (Figure 7B). However, there was another band observed around 31 KDa, which 
could correspond to the molecular weight of GFP (27KDa). In Figure 7B, there were series of 
faint bands between 39KDa and 31KDa, which could be due to partial proteolytic cleavage of 


































Figure 7: (A) Western blotting with anti-cytochrome c antibody, cytochrome C-GFP 
had a band showed ~39 KDa, and cytochrome C band showed ~12KDa. (B) Western 
blotting with anti-EGFP antibody, prominent band showed at 39KDa that illustrate 
cytochrome C is still fused with GFP protein and near 31 KDa representation of 










4.4 Release kinetics of cytochrome C-GFP observed in real time 
The punctuated pattern of cytochrome C-GFP expression became notably diffused after 
the introduction of multiple drugs (TRAIL, Staurosporine, Tarceva). The release time of 
cytochrome C-GFP was monitored through time-lapse fluorescence microscopy at 488/507nm 
excitation/emission. In Figure 8, where the cells were treated with TRAIL (400ng/ml), a majority 
of cytochrome c GFP release was observed between 0.5 and 1 hr. The timing of cytochrome C 
release is dependent on the concentration and types of anti-cancer reagents. However, it was 
observed through time lapse images that different concentrations of apoptosis-inducing reagent 




















Figure 9 (A-E) represents by the normalized standard deviation, where standard derivation is 
divide by its average (CV=STD/Mean). The drop in normalized standard deviation (or 
Coefficient of Variance) corresponds to the cytochrome-c GFP release in the cells as indicated in 
the quantitative analysis of time-lapse images. TRAIL administered at 400ng/ml initiates the 
release of cytochrome C-GFP between 0.5 and 1 hr time points (Figure 9A), that at 100 ng/ml 
Figure 8: (A-D) Sample records from 
the time series fluorescence 
measurement of cytochrome-c GFP 
on living PC-9 cells with 400ng/ml 
TRAIL-induced apoptosis treatment. 
Majority of initiation of cytochrome 
C-GFP release was monitored 
between 0.5 and 1 hr. All the images 






does so between the 2 to 3 hr time points (Figure 9B); a 1µM Staurosporine sample does so 
between the 0.5 and 1hr time points (Figure 9C); and the 200mM Tarceva dose invokes the 
release between the 1 and 1.5 hr time points (Figure 9D).  There was no release measured when 













On the basis of this analysis, we monitored the release of cytochrome C-GFP expression 
under confocal microscope when cells are treated with 400ng/ml TRAIL. Stack of images in the 
z-direction were taken after two hours of giving the drug (Figure 9). Figure 10A, 10B shows the 
middle of the cells where it was observed that GFP signal was completely diffused from the 
mitochondria after two hours of treatment. The overlayed image shows the localization of GFP 
and mitochondria after induction (Figure 10C). The Pearson’s correlation coefficient value was 
Rp=0.45, which indicated that there were almost no co-localizations as observed of the data from 



















Figure 9: Quantitative analysis of the distribution of 
cytochrome C-GFP under apoptosis-inducing 
reagents; TRAIL (100ng/ml, 400ng/ml), 













Figure 10: Colocalization of 
cytochrome C-GFP with 
mitochondria. All the images were 
taken in 40X oil objective under 
confocal microscope. (A) 
Cytochrome C-GFP diffuse into 
cytosol, (B) Cells were stained with 
Mitoctracker for mitochondria, (C) 
Overlay image of cytochrome C-
GFP with mitotracker (D) 
Quantitative analysis of 




4.5 Calibration of Microfluidic Duration Device 
The fluid flow of Microfluidic Duration Device was calculated by stimulating different 
flow rates. Microfluidic Duration device contains series of alternating parallel channels; 
experimental channels and gap channels (Figure 11(i)). In order to deliver the right concentration 
of any soluble stimuli, it is important to calibrate the flow rate by the number of experimental 
channels receiving a certain flow. Therefore, two different food dyes were used in this 
calibration: blue dye characterized a flow rate (QB) of basal culture medium that is delivered 
through the left inlet and red dye characterized a flow rate of stimulus (Q stimulus), which will be 
through the other inlet.  Considering a low Reynolds number <100, we could minimize the 
mixing of two solutions before entering into experimental channels. However, other factors may 
influence the rate or occurrence of diffusion between two solution, therefore gap channels were 
design between each experimental to carry the partially-mixed interface (Figure 11 (i), 11(ii)). By 
using the flow rate at 10µl/min in left inlet and slowly increasing flow rate, starting from 
0.1µl/min, at other inlet will cause fluid flow through the experimental channels without causing 
diffusion. The result from the calibration graph shows that no red channels were filled at flow 
rate of 0.1µl/min; however when flows rate increases to 1 µl/min three channels were filled 
(Figure 11(iii). The result also verified that when red dye flow rate was lower, more experiment 
channels were filled. As the flow rate increased, the number of experiment channels did not 
change (Figure 11(iii)). Also, the profile of flow rate was not dependent on the time. For future 
purposes, we can do drug screening and study the cellular response of cells by controlling the 



































n= number of experimental channels filled with red food dye 
 
Figure 11: (i) AUTOCAD drawing of Microfludic Duration Device, (ii) Representation of Basal medium flow 
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5. Discussion and Conclusion 
In this present study, we used molecular biology techniques coupled with time lapse 
fluorescence microscopy to investigate the release kinetics of cytochrome C-GFP in response to 
three different apoptosis-inducing reagents; TRAIL, Staurosporine, and Tarceva. Previous studies 
have shown that there are multiple mechanisms governing cytochrome C release into cytosol 
simultaneously, but the choice of mechanism is dependent on the nature of apoptotic signal [25]. 
Investigators also found that cytochrome C-GFP release is early during apoptosis and leads 
toward caspase activation [25, 26].  To study the release kinetics of cytochrome C in human lung 
cancer cell (PC-9 cells), we have successfully developed a stable reporter cell line using GFP 
tagged cytochrome C to monitor its release in response to different anti-cancer drugs. The 
reporter cell line was characterized to confirm the existence and localization of cytochrome C-
GFP fusion proteins inside mitochondria before drug stimulation (Figure 3). The release of 
cytochrome C GFP was monitored by time lapse imaging under fluorescence microscopy (Figure 
7 (A-D)).  In agreement with the investigators [27] our data also demonstrated that cytochrome 
C-GFP was released after administration of apoptosis-inducing reagents and activates the 
extrinsic or intrinsic pathway of apoptosis.  
 Initially, it was primary objective to characterize and confirm our constructed reporter 
cell line. The results from western blot using anti-cytochrome C-GFP antibody and anti-EGFP 
antibody confirmed two main purposes. First, it confirmed whether the expression of GFP 
represents the intact cytochrome C-GFP fusion protein within the human lung cancer cell line 
(PC-9). Second, results from western blotting helped to analyze the expression levels of fused 
cytochrome C-GFP protein with the expression levels of endogenous cytochrome C present in 
the reporter cell line.  Our result showed that there were two distinguishable bands at 
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different molecular weight that was exposed to anti-cytochrome C antibody, one between 89KDa 
and 36KDa, and other below 18 KDa (Figure 6A). The band in between 89KDa & 36KDa 
represented the cytochrome C-GFP fusion protein (~39KDa) and the below 18KDa one 
corresponded to the molecular weight of the endogenous cytochrome C, typically around 12KDa. 
This result demonstrated that the constructed reporter cells contain both cytochrome C- GFP 
fusion protein and endogenous cytochrome C. Based on this result, we are confident that our 
cytochrome C reporter cell line can be used to study the dynamic activities of endogenous 
cytochrome C in response to an apoptosis-inducing reagent. These results agree with studies by 
Goldstein et al., 2005 [27] and with the observations from the time lapse fluorescence images 
(Figure 7 (A-D)). A protein band above 36 KDa was observed when anti-EGFP antibody was 
used in the same western blot experiment. The band above 36KDa was expected to be 
cytochrome C –GFP fusion protein (~ 39KDa).  This result also confirmed that cytochrome C-
GFP was still fused together (Figure 6B). However, there were series of faint bands in between 
39KDa and 31KDa which were expected due to the partial proteolytic cleavage of cytochrome 
C-GFP. It was anticipated that an anti-EGFP antibody should depict a band at 27 KDa (the 
molecular weight of GFP), however, no band showed up at this molecular weight. This result 
concluded that there is no complete cleavage of GFP protein from the recombinant cytochrome 
C-GFP.  
The localization of cytochrome C-GFP was also confirmed by confocal microscopy with 
MitoTracker. The overlay image of cytochrome C-GFP with mitotracker red fluorescent dye 
confirmed the punctuated cytochrome C-GFP within mitochondria. Using ImageJ software, we 
were able to generate a colocalization coefficient based on the fluorescence intensity of both 
signals. It was determined that when the GFP signal was punctuated inside the 
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mitochondria, the Pearson’s correlation coefficient (Rp) value was 0.772 (Figure 5C, 5D). 
According to the statistic, when Rp = 1, it is a perfect colocalization; when Rp = 0, it is random; 
and Rp = -1 represents perfect exclusion.  Based on this value, the colocalization coefficient 
between cytochrome C-GFP and MitoTracker dyed mitochondria in our reporter cells was closer 
to 1 but not equal to one. When MitoTracker gets in the mitochondria, it reacts with thiols on 
proteins and peptides to form an aldehyde-fixable conjugate (Invitrogen MitoTracker Manual). 
Most likely MitoTracker shows off all protein locations in mitochondria but cytochrome c-GFP 
only shows where cytochrome C proteins are. 
 We studied the release of cytochrome C from mitochondria in individual human lung 
cancer cells. We found that the timing of cytochrome C release varies under different apoptosis-
inducing reagents. In this study, all the samples were prepared with identical experimental 
conditions (e.g. cell seeding and fluorescence light exposure time). The results concluded that the 
choice of apoptotic pathway (extrinsic or intrinsic) depends on the nature of apoptotic signal. The 
result from the study of cytochrome C-GFP under the stimulation of rhTRAIL demonstrated that 
different concentrations of rhTRAIL affect the release time of cytochrome C-GFP.  When 
100ng/ml of rhTRAIL was introduced to the PC-9 reporter cell line, the diffusion of cytochrome 
C-GFP was noticed between 2 and 3 hours time points (Figure 8A). Increase in the concentration 
of rhTRAIL (400ng/ml) caused the release of cytochrome C-GFP between 0.5 and 1 hour (Figure 
8B). Studies have shown that TRAIL in the human body binds with 5 distinct TRAIL receptors. 
Two of them are DR4 and DR5 [28, 29]. The result from this study illustrated that a high 
presence of pro-apoptotic ligand (TRAIL) caused more binding to the death receptors, eliciting 
an earlier release of cytochrome C-GFP at the high TRAIL concentration.  
 We have found that staurosporine caused the release of cytochrome C-GFP 28 
between the time interval of 0.5 and 1 hour (Figure 8C), similar to release time of cytochrome C-
GFP when 400ng/ml TRAIL was induced.  Preliminary studies have shown that staurosporine is 
a promising anticancer agent that inhibits tumor cell growth by inducing cell death via intrinsic 
apoptotic pathways [30, 31]. Based on our data result, we cannot conclude which pathway lead 
to rapid induction of apoptosis. However, this result does confirm that the releasing time of 
cytochrome C-GFP using in-vitro human model was different from the in-vitro animal model. 
For rat pheochromocytoma-6 (PC-6) cell line, the release time of cytochrome C was noted after 2 
hours [26]. From this study, we can determine that usage of an in-vitro animal model to study the 
mechanism of apoptosis will not be as accurate as using an in-vitro human model, in particular to 
drug screening.  
Tarceva (Erlotnib). Erlotnib is most common anti-cancer drugs for non small cell lung 
cancer. Studies have shown that Erlotnib inhibits tumor cell growth by binding with EGFR 
(Epidermal Growth Factor) [32]. Investigator also found that erlotinib triggers apoptosis through 
the intrinsic pathway [32, 33]. Previous studies have shown that induction of apoptosis by 
erlotinib occurred in a dose and time-dependent manner [32]. We found that 200nM Tarceva 
(erlotnib) invoked cytochrome C-GFP release after 1 hour (Figure 8D).  According to study by 
ling et al., 2008, the non small cell lung cancer treated with 0.1µM erlotinib releases cytochrome 
C after 8 hours. Our result supported the statement that the induction of apoptosis does depend 
on the dosage of erlotinib.  
In addition, our results from the untreated (control) sample confirmed that the short-time 
exposure of blue or green light from fluorescence microscopy itself does not trigger the releaseof 
cytochrome C-GFP. From this result, we can conclude that majority of initiation of apoptosis was 
due to the drug response.  
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In order to confirm if there is a significant difference between the data from time point for 
all three apoptosis-inducing reagents, we performed a two-tailed paired t-test with a confidence 
interval of 95% (p<0.05) for CV (Coefficient of Variance) values across the releasing time. All 
three treated groups had p< 0.05, depicting a significant change over time (CVs at 1 vs.1.5hrs for 
Tarceva; CVs at 0.5 vs. 1hr for 400ng/ml TRAIL; CVs at 2 vs. 3hrs for 100ng/ml TRAIL and 
CVs at 0.5 vs. 1hr for Staurosporine). For the control, there is no statistically significant 
difference emerging over time within the control group using ANOVA (Analysis of Variance)  
During the calibration of the microfluidic duration device, we demonstrated that a ratio of 
100 between flow rates at two inlets would definitely allow cells in every channel expose to the 
type of medium coming from the higher flow rate inlet. By reducing the ratio of flow rates 
between two inlets, the number of micro-channels exposed to a desired stimulation can be 
controlled. However, the upper limit of a flow rate is determinate by the shear stress cells can 
tolerant. For example, a flow rate of 1µl/min gives us the shear stress value of 0.65dyne/cm2, 
which is higher than the recommended limiting shear stress applied to the cell surface shear 
stress (<0.1 dyne/cm2)[21]. This value of shear stress was calculated by the following equation:  
 
zy =6Q/ wh2 
(where Q is flow rate, is viscosity of the fluid, w and h are the channel width and height 
respectively. zy is the stress felt by the cell if it were flat, since it corresponds to the main shear 
forces exerted by the fluid). On the other hand, the lower limit of a flow rate is determined by 
many factors from the limitation of a syringe pump and the lowest flow rate to avoid diffusion at 
the interface of two media.  In addition, it was also discovered that there are several factors 
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that can increase the diffusion between two flows and affect the fluid flow, such as viscosity of 
fluid and bubble formation. Therefore, it is important to consider these scenarios before 
conducting the experiment. The flow rates used in current study may be too high. Further 
calibration experiments need to be done to find an optimized pair to satisfy two conditions, 




















6. Summary and Future Studies 
 
A cytochrome C-GFP reporter cell line was successfully constructed using human lung 
cancer cells. The fusion status of cytochrome C-GFP and its localization in mitochondria was 
confirmed in the reporter cell line. In addition, the release kinetics of cytochrome C-GFP in 
response to three different apoptosis-inducing reagents, TRAIL, Staurosporine, and Tarceva, 
were studied to demonstrate the application of this reporter cell line in the area of anti-cancer 
drug discovery and screening targeting apoptosis pathways. The result from this study illustrated 
that the dynamic release of cytochrome C-GFP is dependent on the cell types and doses.  
The cytochrome c-GFP reporter cell line can be further used to test the natural 
compounds and its potential to trigger apoptosis. The results from this study can be used as a 
control to investigate the apoptosis-inducing ability in the signaling pathways by natural 
compounds that are currently in research, e.g. Actein [35]. It will be interesting to know, which 
pathways of apoptosis Actein may lead to. According to our result, different concentrations of 
rhTRAIL give different release times of cytochrome C-GFP (400 ng/ml rhTRAIL release 
cytochrome C-GFP after 0.5 hrs, which was the similar release time when the cells were exposed 
to Staurosporine). As mentioned before, these two apoptosis-inducing reagents initiates apoptosis 
in two different signaling pathways (extrinsic and intrinsic). Using an earlier detection of 
apoptosis staining dye, Annexin-V, we can monitor which reagent lead to apoptosis faster or 
whether rhTRAIL induces apoptosis associated with the activation of caspases in a dose- and 
time-dependent manner as Tarceva.  
We have also calibrated a microfluidic duration device to investigate the anti-cancer 
drugs response at different duration. In the future, this system can be used to monitor/investigate 
the synergistic drug response in time-series that may be concurrently utilized for more 
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effective cancer treatments. For instance, preliminary data from the combination of bevacizumab 
and erlotinib suggest that it may provide benefit in a broader population of NSCLC (none small 
cell lung cancer) than each agent individually [34].  Using our reporter cell line in our 
microfluidic duration device we can study the synergistic effects of these two anti-cancer 
reagents (e.g. what is the optimized time interval between applying two drugs in order to reach a 
maximum therapeutic effects). As a result, our system can facilitate the development of improved 
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